ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).
"We are pleased to report that Nasdaq has recognized our full compliance with their listing requirements," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "Their confirmation follows our successful efforts to improve our balance sheet, including raising new capital and implementing a reverse share split."
About NLS Pharmaceutics Ltd.
NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
Contact:
Investor Relations Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.nlspharma.com
Last Trade: | US$3.13 |
Daily Change: | -0.21 -6.29 |
Daily Volume: | 45,600 |
Market Cap: | US$146.730M |
October 21, 2024 October 15, 2024 June 28, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB